Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of AZD9550 + AZD6234 for weight loss in adults with obesity or overweight with comorbidities
2024-516176-15-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Modality
- Small Molecules, Peptides
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of AZD9550 and lenbelintide in obesity and Overweight (4 arms), sponsored by AstraZeneca. Primary endpoints: Percent change in body weight from baseline after 36 weeks of treatment and Weight loss ≥ 5% from baseline after 36 weeks of treatment (primary). Started Feb 2025; status: completed.
02
Drugs
AZD9550lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2024-516176-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516176-15-00.